Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide in Type 1 Diabetes with Obesity
NCT06909006Phase 3Not yet recruiting
- Sponsor
- Nordsjællands Hospital
- Start
- Oct 2025
- Primary completion
- Jun 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in type 1 diabetes mellitus (T1D), obesity, sponsored by Nordsjællands Hospital. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
03
Conditions
type 1 diabetes mellitus (T1D)obesity
Beyond the preview
Go deeper on NCT06909006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06909006.